Pradofloxacin

DB11453ExperimentalVet approvedSmall molecule

Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs...

Mechanism: Pharmacologically active on DNA topoisomerase 4 subunit A, DNA gyrase subunit B, and DNA topoisomerase 4 subunit B
Curator reviewed
Formula / weight: C₂₁H₂₁FN₄O₃ · 396.422 g/mol (avg)

Resolves to

Compound

UNII6O0T5E048ICAS195532-12-8ChEMBLCHEMBL1256815

Clinical / RWD

RxNorm1367269

Structure

InChIKeyLZLXHGFNOWILIY-APPDUMDISA-NSMILES[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1C#N)C(O)=O

Targets

P0AFI2parCP0AES6gyrBP0A0K8gyrBP20083parEP0AES4gyrAP0C1U9parCP20831gyrA

What you can answer from here — as of August 16, 2026

7Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

17+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pradofloxacin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account